New York, Jan 26, 2026, 16:37 EST — After-hours
- Moderna shares ended down 1.5%, holding steady after hours
- The company scheduled its fourth-quarter results and corporate update for Feb. 13
- Biotech ETFs showed a mixed performance, while big pharma stocks moved unevenly
Moderna, Inc. shares closed Monday down 1.5% at $47.98. In after-hours trading, which follows the 4 p.m. close, the stock held steady around $47.99. 1
The vaccine maker announced Monday it will release its fourth-quarter 2025 results on Feb. 13, followed by a conference call and webcast at 8 a.m. ET. Executives are set to provide a corporate update during the session. 2
Investors are now eyeing that date as the next key checkpoint to assess how rapidly Moderna can stabilize both revenue and expenses while shifting focus beyond its COVID-19 portfolio.
Biotech stocks saw mixed action. The iShares Nasdaq Biotechnology ETF edged up roughly 0.3% late Monday, but the SPDR S&P Biotech ETF slipped a bit.
Moderna’s Feb. 13 call will probably zero in on the data rather than headlines: how demand is shaping up for its respiratory vaccines, the speed of its R&D spending, and any changes to timelines for major projects.
Shares diverged among peers. Merck, partnered with Moderna in oncology, slipped roughly 0.8%, while Pfizer climbed nearly 0.9%.
The stock has seen wild swings this January. It surged 15.8% on Jan. 21, climbed another 4.1% the following day, then dropped 6.1% on Jan. 23, and slid further on Monday. 3
Bulls face the risk that the next update could shift expectations unfavorably — weaker vaccine demand, rising costs, or slower clinical progress might drag shares down fast, especially following recent swings.
Next on the docket: Moderna reports earnings on Feb. 13, followed by a conference call at 8 a.m. ET. Investors are set to challenge management on 2026 goals and the outlook heading into 2027.
